View Future GrowthCHO Pharma 과거 순이익 실적과거 기준 점검 0/6CHO Pharma은 연평균 0.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.9%의 비율로 증가했습니다. 매출은 연평균 16.8%의 비율로 증가했습니다.핵심 정보0.64%순이익 성장률4.23%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률18.53%매출 성장률16.75%자기자본이익률-11.77%순이익률-20,265.97%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updatesReported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.공시 • Mar 27CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026. Location: 2 floor building. c no,99 ln.130, sec.1 yen chiu yuan rd., nangang district, taipei city TaiwanNew Risk • Mar 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$101k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$102k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).공시 • Mar 03CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025.New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k).공시 • Mar 17CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024.New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director & Member of Scientific Advisory Board Mei-Shang Ho was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Liu Shuan-Ta was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.분석 기사 • Mar 24Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Jan 06New 90-day low: NT$24.15The company is down 16% from its price of NT$28.80 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period.분석 기사 • Dec 09We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Dec 09New 90-day low: NT$25.10The company is down 16% from its price of NT$30.00 on 10 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.Is New 90 Day High Low • Oct 22New 90-day low: NT$28.30The company is down 20% from its price of NT$35.35 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.매출 및 비용 세부 내역CHO Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TPEX:6586 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비31 Dec 251-2904028730 Sep 252-2603726130 Jun 253-2303523531 Mar 253-2213322731 Dec 244-2123221930 Sep 242-2343220930 Jun 241-2553319931 Mar 241-2813121931 Dec 230-3063023930 Sep 230-3172727730 Jun 230-3272431531 Mar 230-3332432131 Dec 220-3382532630 Sep 222-2982428430 Jun 224-2572324231 Mar 224-2322221831 Dec 214-2062019430 Sep 212-2232121230 Jun 210-2402123031 Mar 210-2692125931 Dec 200-2972228830 Sep 200-3282331730 Jun 200-3592434731 Mar 200-3592434631 Dec 190-3582534530 Sep 190-3472433530 Jun 190-3372332531 Mar 190-3222331131 Dec 180-3072229730 Sep 180-3092729530 Jun 180-3123229431 Mar 180-3103429131 Dec 170-3093528930 Sep 171-2933227630 Jun 171-2783026431 Mar 171-2622525431 Dec 162-2452124330 Sep 161-2031421130 Jun 161-161717831 Mar 160-1353160양질의 수익: 6586 은(는) 현재 수익성이 없습니다.이익 마진 증가: 6586는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6586는 수익성이 없지만 지난 5년 동안 연평균 0.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 6586의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 6586은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6586는 현재 수익성이 없으므로 자본 수익률이 음수(-11.77%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/10 00:46종가2026/07/09 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CHO Pharma, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 26Full year 2025 earnings released: NT$1.36 loss per share (vs NT$0.99 loss in FY 2024)Full year 2025 results: NT$1.36 loss per share (further deteriorated from NT$0.99 loss in FY 2024). Net loss: NT$290.0m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
공시 • Mar 27CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026CHO Pharma, Inc., Annual General Meeting, Jun 25, 2026. Location: 2 floor building. c no,99 ln.130, sec.1 yen chiu yuan rd., nangang district, taipei city Taiwan
New Risk • Mar 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$101k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$3.2m revenue, or US$102k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
공시 • Mar 03CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025CHO Pharma, Inc., Annual General Meeting, Jun 26, 2025.
New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$1m (NT$1.1m revenue, or US$33k).
공시 • Mar 17CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024CHO Pharma, Inc., Annual General Meeting, Jun 27, 2024.
New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (NT$60k revenue, or US$1.9k). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director & Member of Scientific Advisory Board Mei-Shang Ho was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Liu Shuan-Ta was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 27Full year 2020 earnings released: NT$1.62 loss per share (vs NT$1.96 loss in FY 2019)Full year 2020 results: Net loss: NT$296.8m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
분석 기사 • Mar 24Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Jan 06New 90-day low: NT$24.15The company is down 16% from its price of NT$28.80 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 14% over the same period.
분석 기사 • Dec 09We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Dec 09New 90-day low: NT$25.10The company is down 16% from its price of NT$30.00 on 10 September 2020. The Taiwanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period.
Is New 90 Day High Low • Oct 22New 90-day low: NT$28.30The company is down 20% from its price of NT$35.35 on 24 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.